Uniphar plc, the Dublin-headquartered international diversified healthcare services business, has announced a series of board-level changes effective in late 2026 and early 2027. Roger Gillespie, a Chartered Accountant and former KPMG partner of over four decades, has been approved as an independent non-executive Director with effect from 25 January 2027. Separately, Paul Hogan assumed the role of Chair on 18 November 2026, succeeding Maurice Pratt, who served in that capacity for 17 years. The changes represent a significant shift in Uniphar's board composition as the company continues its international expansion across Europe, North America, APAC and MENA.

Key Points

  • Uniphar plc (UPR) — international diversified healthcare services group headquartered in Dublin, Ireland
  • Roger Gillespie appointed independent non-executive Director with effect from 25 January 2027; Paul Hogan became Chair on 18 November 2026
  • Maurice Pratt stepped down as Chair on 18 November 2026 but will remain on the Board as a Director until 6 May 2027; Sue Webb assumed the Senior Independent Director role on the same date
  • Investors may be watching how the refreshed board steers Uniphar's three-division structure — Pharma, Medtech, and Supply Chain & Retail — across its 160-plus country delivery network

Roger Gillespie's Four-Decade KPMG Career Brings Audit and Deal Advisory Expertise to Uniphar Board

Roger Gillespie joins the Uniphar board with a career background spanning more than four decades at KPMG, where he held roles as both Audit Partner and Deal Advisory Partner. The announcement states he worked closely with some of Ireland's largest publicly listed and private companies across the healthcare, industrial, retail, and agri-food sectors. Since retiring from KPMG in 2024, he has provided consultancy services and holds a number of non-executive board positions, including in the healthcare sector. The company highlights that Gillespie brings expertise in financial reporting, corporate governance, equity capital and debt markets, and mergers and acquisitions — areas of direct relevance to Uniphar's growth-oriented strategy.

Paul Hogan Assumes Chair Role as Maurice Pratt Ends 17-Year Tenure Leading Uniphar's Board

Paul Hogan formally became Chair of Uniphar on 18 November 2026, with Maurice Pratt stepping down from that role on the same date. The announcement confirms that Pratt, who served on the Uniphar board for over 20 years including 17 years as Chair, will remain as a Director until 6 May 2027. Chief Executive Officer Ger Rabbette's remarks in the announcement credit Pratt with guiding the company through the aftermath of the 2008 financial crisis, the acquisition of CMR, geographic expansion into Europe and the United States, and the company's flotation in 2019. Sue Webb simultaneously assumed the role of Senior Independent Director, replacing Paul Hogan in that capacity.

Uniphar's Three-Division Healthcare Model Provides Context for Governance Reinforcement

Uniphar services more than 200 multinational pharmaceutical and medical technology manufacturers across its three divisions: Uniphar Pharma, Uniphar Medtech, and Uniphar Supply Chain & Retail. The group delivers to more than 160 countries and is active in Europe, North America, APAC, and MENA. Uniphar Supply Chain & Retail is described as the leading pharmaceutical wholesaler in Ireland, while Uniphar Medtech operates as a pan-European medical device distributor. These structural complexities — spanning multiple regulatory environments and capital requirements — make the board-level financial and governance expertise that Gillespie brings particularly pertinent for investors monitoring the company's ongoing international development.